92 121

Cited 59 times in

Detection of Phenolic Glycolipid I of Mycobacterium leprae in Sera from Leprosy Patients before and after Start of Multidrug Therapy

 Sang-Nae Cho  ;  Roland V. Cellona  ;  Laarni G. Villahermosa  ;  Tranquilino T. Fajardo, Jr.  ;  M. Victoria F. Balagon  ;  Rodolfo M. Abalos  ;  Esterlina V. Tan  ;  Gerald P. Walsh  ;  Joo-Deuk Kim  ;  Patrick J. Brennan 
 Clinical and Diagnostic Laboratory Immunology, Vol.8(1) : 138-142, 2001 
Journal Title
 Clinical and Diagnostic Laboratory Immunology 
Issue Date
A total of 100 untreated new leprosy patients were recruited prospectively and examined for the presence of phenolic glycolipid I (PGL-I) antigen in their serum specimens by dot enzyme-linked immunosorbent assay (ELISA) using rabbit anti-PGL-I antiserum. The presence of circulating PGL-I antigen was closely related to the bacterial indices (BI) of the patients. The PGL-I antigen was detectable in 27 (93.1%) of 29 patients with a BI of 4.0 or above and in 15 (68.2%) of 22 patients with a BI of 3.0 to 3.9. However, none of the 37 patients with a BI of less than 1.9 had detectable PGL-I antigen by the methods used in this study. The level of PGL-I in serum declined rapidly by about 90% 1 month after the start of multidrug therapy. This study showed clearly that anti-PGL-I IgM antibodies and circulating PGL-I antigen levels reflect the bacterial loads in untreated leprosy patients. The serological parameters based on the PGL-I antigen may therefore be useful in the assessment of leprosy patients at the time of diagnosis and possibly in monitoring patients following chemotherapy.
Files in This Item:
T200103143.pdf Download
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Microbiology (미생물학교실)
Yonsei Authors
조상래(Cho, Sang Nae)
RIS (EndNote)
XLS (Excel)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.